These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Vohora D Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473 [TBL] [Abstract][Full Text] [Related]
5. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
6. New antipsychotic medications: do research results relate to clinical practice? MacEwan GW Can J Psychiatry; 1993 Sep; 38 Suppl 3():S75-9. PubMed ID: 7504572 [TBL] [Abstract][Full Text] [Related]
7. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Motlová L; Spaniel F; Höschl C; Balon R Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853 [TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. Nasrallah HA; Tandon R J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142 [TBL] [Abstract][Full Text] [Related]
9. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy. Wehnert A Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the pharmacotherapy of schizophrenia. Borison RL Harv Rev Psychiatry; 1997; 4(5):255-71. PubMed ID: 9385002 [TBL] [Abstract][Full Text] [Related]
11. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618 [TBL] [Abstract][Full Text] [Related]
13. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691 [TBL] [Abstract][Full Text] [Related]
14. Use and safety of antipsychotic drugs during pregnancy. Einarson A; Boskovic R J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391 [TBL] [Abstract][Full Text] [Related]
15. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. Kane JM J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086 [TBL] [Abstract][Full Text] [Related]
16. Selection of atypical antipsychotics for the management of schizophrenia. Sprague DA; Loewen PS; Raymond CB Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593 [TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy and the natural course of schizophrenia. Davis JM J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252 [TBL] [Abstract][Full Text] [Related]
20. Factors which can make patients difficult to treat. Kane JM Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650 [No Abstract] [Full Text] [Related] [Next] [New Search]